RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsThis would appear as a 'good thing' as this is an example of Big Pharma beginning to come out of 'stealth mode' and are unveiling their otherwise covert interests in expanding their pipelines into immuno-oncology agents and combination I/O therapies that work synergistically to stimulate the immune system for the body to effectively target and kill various cancers.